Blocknomi
TLDR BOT+BAL delivers 21.2-month median survival in refractory MSS colorectal cancer. Three-year overall survival reaches 33% in Agenus’ fully enrolled Phase 1b cohort. Confirmed response rate hits 21%, including three…
Related articles
-
Bitcoin’s Five-Day Surge to $77K: What Cost-Basis Levels Reveal
Blocknomi Published 23.08.2026 22:24
-
Ripple's RLUSD Zeros In on PayPal USD as Its Market Cap Tops $2 Billion
U.Today Published 21.08.2026 20:12
-
Bitcoin rally sends Upbit trading volume up 273% to $1.84 billion
Crypto.News Published 21.08.2026 09:45
-
Crude Oil Surges for Third Consecutive Session Amid U.S.-Iran Conflict in Persian Gulf
Blocknomi Published 02.09.2026 09:53
-
Solana (SOL) Eyes $150 Breakout Following Record-Breaking Network Activity in August
Blocknomi Published 02.09.2026 06:50
-
Upbit volume hits 1.15 trillion won during flash crash
Crypto.News Published 23.08.2026 10:06
-
Stagwell (STGW) Stock: Instrument Strengthens Creative Leadership With De Caluwé Return
Blocknomi Published 24.08.2026 18:22
-
Adam Back Puts €7.6 Million Into Capital B to Buy More Bitcoin
BeInCrypto Published 02.09.2026 12:00